PRPH - ProPhase Labs, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.96
-0.16 (-3.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.12
Open4.03
Bid0.00 x 1400
Ask0.00 x 1100
Day's Range3.95 - 4.13
52 Week Range1.85 - 6.64
Volume22,312
Avg. Volume38,787
Market Cap44.074M
Beta0.79
PE Ratio (TTM)1.48
EPS (TTM)2.67
Earnings DateAug 9, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-05-18
1y Target Est15.55
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2018

    DOYLESTOWN, Pa., May 14, 2018-- ProPhase Labs, Inc. today reported its financial results for the three months ended March 31, 2018. Net sales from continuing operations were $3.4 million for the three ...

  • GlobeNewswire17 days ago

    PROPHASE LABS, INC. ANNOUNCES SPECIAL CASH DIVIDEND

    ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com), a vertically integrated and diversified branding, marketing and technology company with deep experience in over-the-counter dietary supplements and remedies (“ProPhase” or “Company”), announced today that its Board of Directors has declared a special cash dividend in the amount of $1.00 per share on its common stock, payable on June 5, 2018 to stockholders of record as of May 21, 2018. “We are pleased to return to our stockholders a common dividend of $1.00 per share, which represents 34.6% of its closing price of $2.89 per share as of May 7, 2018.  This dividend provides an immediate benefit to our stockholders, while allowing us to remain well positioned for future growth with ample liquidity for strategic opportunities that may arise,” said Ted Karkus, Chairman and Chief Executive Officer of ProPhase.

  • GlobeNewswire2 months ago

    ProPhase Labs Reports Financial Results for the Year Ended December 31, 2017

    DOYLESTOWN, Pa., March 21, 2018-- ProPhase Labs, Inc., today reported its net sales from continuing operations were $9.9 million for the year ended December 31, 2017, as compared to net sales of $4.2 million ...

  • ACCESSWIRE2 months ago

    ProPhase Labs, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 21, 2018 / ProPhase Labs, Inc. (NASDAQ: PRPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 21, 2018 at 11:00 AM Eastern Time. ...

  • GlobeNewswire2 months ago

    ProPhase Labs to Release Fiscal 2017 Results on Wednesday, March 21st

    DOYLESTOWN, Pa., March 16, 2018-- ProPhase Labs announced today that financial results for the year ended December 31, 2017, will be released before the market opens on Wednesday, March 21, 2018. A conference ...

  • American City Business Journals5 months ago

    ProPhase completes $4.5M tender offer

    ProPhase Labs Inc. is buying back $4.5 million of its common stock, completing a tender offer announced earlier this month. The Doylestown, Pa., natural health products company said Thursday it has accepted for purchase about 1.95 million shares at $2.30 per share. ProPhase is the original developer of Cold-Eeze zinc lozenges for cold suffers.

  • Can ProPhase Labs Inc (PRPH) Continue To Outperform Its Industry?
    Simply Wall St.6 months ago

    Can ProPhase Labs Inc (PRPH) Continue To Outperform Its Industry?

    ProPhase Labs Inc (NASDAQ:PRPH) delivered an ROE of 70.52% over the past 12 months, which is an impressive feat relative to its industry average of 16.15% during the same period.Read More...

  • ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 24, 2017
    Capital Cube6 months ago

    ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 24, 2017

    Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nature’s Sunshine Products, Inc., Cyanotech Corporation, XOMA Corporation and True Drinks Holdings, Inc. (MTEX-US, RELV-US, ... Read more (Read more...)

  • Is ProPhase Labs Inc (PRPH) A Buy At Its Current Price?
    Simply Wall St.8 months ago

    Is ProPhase Labs Inc (PRPH) A Buy At Its Current Price?

    ProPhase Labs Inc (NASDAQ:PRPH) is trading with a trailing P/E of 2.4x, which is lower than the industry average of 24.1x. While this makes PRPH appear like a great stockRead More...

  • ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017
    Capital Cube9 months ago

    ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017

    Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nutraceutical International Corporation, Nature’s Sunshine Products, Inc., Oragenics, Inc., Cyanotech Corporation and XOMA Corporation (MTEX-US, ... Read more (Read more...)

  • Marketwired11 months ago

    ProPhase Labs Repurchases 1,061,980 Shares of Its Common Stock

    ProPhase Labs, Inc. today reported that that on June 12, 2017 it entered into a Stock Purchase Agreement with each of Mark S. Leventhal, a former director of the Company, and certain other persons and ...